Cipepofol
| Clinical data | |
|---|---|
| Trade names | Cypsedo |
| Other names | Ciprofol; CS-0064163; CS0064163; GTPL10812; GTPL-10812; HSK-3486; HSK3486; HY-116152; HY116152; (R)-2-(1-Cyclopropylethyl)-6-isopropylphenol |
| AHFS/Drugs.com | cypsedo |
| License data | |
| Routes of administration | Intravenous infusion |
| Drug class | GABAA receptor positive allosteric modulator |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | Liver glucuronidation |
| Excretion | Kidney |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C14H20O |
| Molar mass | 204.313 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Cipepofol (INN, USAN), also known as ciprofol or by its developmental code name HSK3486, sold under the brand name Cypsedo, is a general anesthetic related to propofol which is used for anesthesia and sedation. The drug is used by intravenous infusion. A short-acting and highly selective GABAA positive allosteric modulator, ciprofol is 4 to 6 times more potent than other phenol derivatives such as propofol or fospropofol.
In May 2026, cipepofol was approved by the US FDA. Manufactured by Haisco Pharmaceutical Group of Chengdu, Sichuan, China, ciprofol underwent phase I and II trials in Australia and China. In these early studies, ciprofol was comparable in efficacy to propofol and was associated with fewer adverse events.
Category:
- Drugs not assigned an ATC code